<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR65">
 <label>65.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Tao</surname>
    <given-names>JJ</given-names>
   </name>
   <name>
    <surname>Cangemi</surname>
    <given-names>NA</given-names>
   </name>
   <name>
    <surname>Makker</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Cadoo</surname>
    <given-names>KA</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>JF</given-names>
   </name>
   <name>
    <surname>Rasco</surname>
    <given-names>DW</given-names>
   </name>
   <name>
    <surname>Navarro</surname>
    <given-names>WH</given-names>
   </name>
   <name>
    <surname>Haqq</surname>
    <given-names>CM</given-names>
   </name>
   <name>
    <surname>Hyman</surname>
    <given-names>DM</given-names>
   </name>
  </person-group>
  <article-title>First-in-human phase I study of the activin a inhibitor, STM 434, in patients with granulosa cell ovarian cancer and other advanced solid tumors</article-title>
  <source>Clin Cancer Res</source>
  <year>2019</year>
  <volume>25</volume>
  <issue>18</issue>
  <fpage>5458</fpage>
  <lpage>5465</lpage>
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1065</pub-id>
  <?supplied-pmid 31068369?>
  <pub-id pub-id-type="pmid">31068369</pub-id>
 </element-citation>
</ref>
